Awareness and early recognition of cancer therapy-related cardiotoxicity, along with appropriate surveillance and prevention strategies, can improve cardiac survival and patient outcomes.
Answers are grounded in this paper and cite their sources.
Prompts clinician awareness of cardiotoxicity risks in cancer therapy; leaves open validation of surveillance strategies in prospective studies.
With the improvement in cancer survival, long-term cardiotoxicity has become an area of increased interest. Various cancer therapies, including chemotherapy and radiation therapy can lead to cardiac toxicities with both acute and chronic manifestations. Awareness and early recognition can lead to improvement in cardiac survival and patient outcomes. The focus of this review is to summarize the cancer therapy agents most often associated with cardiovascular side effects, highlighting their mechanism of action and strategies for surveillance and prevention.
No takes yet. Share an insight, caveat, or question.
Hamo et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: